{"id":"W3165395110","doi":"10.1136/annrheumdis-2021-eular.535","title":"POS0087 LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 3 YEARS FROM THE SELECT-COMPARE STUDY","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval","funders":"Genentech; Astellas Pharma; Eisai; Daiichi-Sankyo; Chugai Pharmaceutical; Celltrion; Regeneron Pharmaceuticals; Gilead Sciences; AbbVie; Daiichi Sankyo Europe; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Celgene; Myriad Genetics; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Adalimumab; Rheumatoid arthritis; Discontinuation; Adverse effect; Internal medicine; Methotrexate; Randomized controlled trial; Placebo; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002523086,0.001074123,0.00273228,0.0003909688,0.0004335238,0.001301089,0.0005588327,0.001317163,0.002929901],"category_scores_gemma":[0.002093916,0.0004062283,0.004057079,0.0005450633,0.0008024093,0.001604059,0.0006214503,0.001989457,0.0009596677],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006400561,"about_ca_system_score_gemma":0.0005651865,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006740948,"about_ca_topic_score_gemma":0.001151819,"domain_scores_codex":[0.9989349,0.0004086795,0.0001140321,0.000191756,0.0001850154,0.000165446],"domain_scores_gemma":[0.9980807,0.0006394542,0.0005975807,0.000188388,0.0001781582,0.0003157127],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8868623,0.003075264,0.06077194,0.0008619199,0.008055997,0.0002240102,0.0001413665,0.00122787,0.003986389,0.0002193222,0.001555078,0.03301849],"study_design_scores_gemma":[0.3305099,0.2491449,0.3817664,0.0002964099,0.02407288,0.001025303,0.0005298966,0.002775242,0.003618368,0.0007575753,0.005277447,0.0002257477],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931805,0.003872216,0.0001396788,0.000134451,0.00008903949,0.00008015193,0.001469685,0.00001849455,0.001015866],"genre_scores_gemma":[0.993543,0.001356938,0.0001545758,0.0003283634,0.0002043737,0.0001348757,0.003473899,0.00001179519,0.0007920636],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002929901,"threshold_uncertainty_score":0.01334345,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02352162895562803,"score_gpt":0.2908761858874583,"score_spread":0.2673545569318303,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}